ML 2-23
ML 2-23 is a PROTAC degrader that recruits RNF114 to target BCR-ABL/c-ABL for degradation. ML 2-23 promotes proteasome-dependent degradation of the target protein and inhibits phosphorylation of downstream CRKL. At concentrations used for BCR-ABL degradation, ML 2-23 only causes slight impairment to the viability of cancer cells. ML 2-23 can be used in the research of chronic myeloid leukemia.
(Pink: Bcr-Abl Target protein ligand; Blue: RNF114 ligand (HY-28328); Black: linker).
For research use only. We do not sell to patients.
- Formula: C47H53BrCl2N10O7S
- Molecular Weight:1052.86
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
BCR-ABL |
c-ABL |
In Vitro
ML 2-23 (0.01-5 μM; 16 h) reduces the protein levels of BCR-ABL and c-ABL in K562 cells in a concentration-dependent manner, with a stronger degradation effect on BCR-ABL than on c-ABL, while simultaneously decreasing the phosphorylation of CRKL, a downstream substrate of BCR-ABL. It only slightly reduces the viability of K562 cells in WST assays, indicating that the observed protein reduction is not caused by general cytotoxicity under the concentration and treatment time used to evaluate BCR-ABL degradation[1].
Pretreatment with ML 2-23 (1 μM; 12 h; 30 min pretreatment with 5 μM MG132 (HY-13259)) significantly reverses the ML 2-23-induced degradation of BCR-ABL and c-ABL in K562 cells, indicating that this degradation is proteasome-dependent[1].
ML 2-23 (5 μM; 16 h) does not significantly affect BCR-ABL mRNA levels in K562 cells, but increases c-ABL mRNA levels, indicating that the reduction in BCR-ABL and c-ABL proteins is not caused by transcriptional downregulation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:K562 chronic myeloid leukemia cells
-
Concentration:0.01, 0.1, 0.5, 1, 5 μM
-
Incubation Time:16 h
-
Result:Concentration-dependently reduced BCR-ABL and c-ABL protein levels, preferentially degraded BCR-ABL over c-ABL, and decreased p-CRKL levels.
-
Cell Line:K562 chronic myeloid leukemia cells
-
Concentration:MG132: 5 μM; 1 μM
-
Incubation Time:MG132 pretreatment for 30 min; ML 2-23 treatment for 12 h
-
Result:Reduced BCR-ABL and c-ABL protein levels; MG132 pretreatment significantly rescued the degradation.
-
Cell Line:K562 chronic myeloid leukemia cells
-
Concentration:5 μM
-
Incubation Time:16 h
-
Result:Did not significantly alter BCR-ABL mRNA levels but increased c-ABL mRNA levels.
Chemical Information
-
Molecular Weight 1052.86
-
Formula C47H53BrCl2N10O7S
-
SMILES
O=C(COC1=CC=C(C2CC(C3=CC=C(Br)C=C3)=NN2C(CCl)=O)C=C1)NCCOCCOCCOCCN4CCN(C5=NC(C)=NC(NC6=NC=C(C(NC7=C(C)C=CC=C7Cl)=O)S6)=C5)CC4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)